Journal of Preventive Medicine and Public Health

Munseok Seo

2 Articles

Demographic and Survivorship Disparities in Non–muscle-invasive Bladder Cancer in the United States: Munseok Seo, James R. Langabeer II; J Prev Med Public Health. 2018;51(5):242-247. Published online August 23, 2018; DOI: https://doi.org/10.3961/jpmph.18.092

5,915 View
156 Download
14 Crossref

Objectives
To examine survivorship disparities in demographic factors and risk status for non–muscle-invasive bladder cancer (NMIBC), which accounts for more than 75% of all urinary bladder cancers, but is highly curable with early identification and treatment. Methods: We used the US National Cancer Institute’s Surveillance, Epidemiology, and End Results registries over a 19-year period (1988-2006) to examine survivorship disparities in age, sex, race/ethnicity, and marital status of patients and risk status classified by histologic grade, stage, size of tumor, and number of multiple primary tumors among NMIBC patients (n=29 326). We applied Kaplan-Meier (K-M) and Cox proportional hazard methods for survival analysis. Results: Among all urinary bladder cancer patients, the majority of NMIBCs were in male (74.1%), non-Latino white (86.7%), married (67.8%), and low-risk (37.6%) to intermediate-risk (44.8%) patients. The mean age was 68 years. Survivorship (in median life years) was highest for non-Latino white (5.4 years), married (5.4 years), and low-risk (5.7 years) patients (K-M analysis, p<0.001). We found significantly lower survivorship for elderly, male (female hazard ratio [HR], 0.96), Latino (HR, 1.20), and unmarried (married HR, 0.93) patients. Conclusions: Survivorship disparities were ubiquitous across age, sex, race/ethnicity, and marital status groups. Non-white, unmarried, and elderly patients had significantly shorter survivorship. The implications of these findings include the need for a heightened focus on health policy and more organized efforts to improve access to care in order to increase the chances of survival for all patients.

Summary

Citations

Citations to this article as recorded by

N6-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges
Congjie Xu, Jiaquan Zhou, Xiaoting Zhang, Xinli Kang, Shuan Liu, Mi Song, Cheng Chang, Youtu Lin, Yang Wang
Cellular & Molecular Biology Letters.2024;[Epub] CrossRef
Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer
Angela Estevez, Sumedh Kaul, Aaron Fleishman, Ruslan Korets, Peter Chang, Andrew Wagner, Joaquim Bellmunt, Aria F. Olumi, Heidi Rayala, Boris Gershman
Urologic Oncology: Seminars and Original Investigations.2023; 41(5): 255.e15. CrossRef
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
Kristin Grabe-Heyne, Christof Henne, Paramananthan Mariappan, Götz Geiges, Johannes Pöhlmann, Richard F. Pollock
Frontiers in Oncology.2023;[Epub] CrossRef
Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR)
Mihaela Georgiana Musat, Christina Soeun Kwon, Elizabeth Masters, Slaven Sikirica, Debduth B Pijush, Anna Forsythe
ClinicoEconomics and Outcomes Research.2022; Volume 14: 35. CrossRef
Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013
Kelly K. Bree, Yong Shan, Patrick J. Hensley, Niyati Lobo, Chengrui Hu, Douglas S. Tyler, Karim Chamie, Ashish M. Kamat, Stephen B. Williams
JAMA Network Open.2022; 5(3): e223050. CrossRef
Gender Disparities in Bladder Cancer-Specific Survival in High Poverty Areas Utilizing Ohio Cancer Incidence Surveillance System (OCISS)
Laura Bukavina, Megan Prunty, Kirtishri Mishra, Helen Sun, David Sheyn, Britt Conroy, Amr Mahran, Gregory MacLennan, Fredrick Schumacher, Lee Ponsky, Sarah Markt
Urology.2021; 151: 163. CrossRef
Comparison of survival in elderly patients treated with uretero-cutaneostomy or ileal conduit after radical cystectomy
Shang Huang, Hanzhong Chen, Teng Li, Xiaoyong Pu, Jiumin Liu, Xuecheng Bi
BMC Geriatrics.2021;[Epub] CrossRef
Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions
Kuan-Wei Shih, Wei-Chieh Chen, Ching-Hsin Chang, Ting-En Tai, Jeng-Cheng Wu, Andy C. Huang, Ming-Che Liu
Aging and disease.2021; 12(3): 868. CrossRef
The impact of the social construct of race on outcomes among bacille Calmette‐Guérin‐treated patients with high‐risk non‐muscle–invasive bladder cancer in an equal‐access setting
Corinne Lawler, Lin Gu, Lauren E. Howard, Brandee Branche, Emily Wiggins, Aditya Srinivasan, Meagan L. Foster, Zachary Klaassen, Amanda M. De Hoedt, Jeffrey R. Gingrich, Dan Theodorescu, Stephen J. Freedland, Stephen B. Williams
Cancer.2021; 127(21): 3998. CrossRef
Effect of Intravesical Chemotherapy on the Survival of Patients with Non-Muscle-Invasive Bladder Cancer Undergoing Transurethral Resection: A Retrospective Cohort Study Among Older Adults
Ashis K. Das, Devi K. Mishra, Saji S. Gopalan
The Open Urology & Nephrology Journal.2021; 14(1): 20. CrossRef
Marital Status and Prognostic Nomogram for Bladder Cancer With Distant Metastasis: A SEER-Based Study
Liangjun Tao, Xinyuan Pan, Lixiang Zhang, Jiawei Wang, Zican Zhang, Li Zhang, Chaozhao Liang
Frontiers in Oncology.2020;[Epub] CrossRef
Back pain following instillations of BCG for superficial bladder cancer is not a reactive complication: review of 30 Mycobacterium bovis BCG vertebral osteomyelitis cases
Simon Cadiou, Omar Al Tabaa, Chi-Duc Nguyen, Marine Faccin, Raphaël Guillin, Matthieu Revest, Pascal Guggenbuhl, Eric Houvenagel, Edouard Pertuiset, Guillaume Coiffier
Clinical Rheumatology.2019; 38(6): 1773. CrossRef
Does Health Insurance Modify the Association Between Race and Cancer-Specific Survival in Patients with Urinary Bladder Malignancy in the U.S.?
Juliana Morales, Aaron Malles, Marrell Kimble, Pura Rodriguez de la Vega, Grettel Castro, Alan M. Nieder, Noël C. Barengo
International Journal of Environmental Research and Public Health.2019; 16(18): 3393. CrossRef
Чи може бути гормонотерапія елементом комбінованого радикального лікування хворих на низькодиференційований рак сечового міхура?
P. G. Yakovlev
Шпитальна хірургія. Журнал імені Л. Я. Ковальчука.2019; (3): 75. CrossRef

Determinants of Potentially Unnecessary Cervical Cancer Screenings in American Women: Munseok Seo, James R. Langabeer II; J Prev Med Public Health. 2018;51(4):181-187. Published online June 7, 2018; DOI: https://doi.org/10.3961/jpmph.18.023

5,196 View
158 Download
3 Crossref

Abstract PDF

Objectives
To identify factors responsible for potentially clinically unnecessary cervical cancer screenings in women with prior hysterectomy.
Methods
A retrospective cross-sectional study was conducted using the Centers for Disease Control and Prevention’s Behavioral Risk Factor Surveillance System (BRFSS). This study targeted adult women and examined whether they received a both a Papanicolaou (Pap) test and undergone a hysterectomy in the last three years. We conducted multivariate analyses, including weighted proportions and odds ratios (ORs), based on the modified BRFSS weighting method (raking). The inclusion criteria were adult women (>18 years old) who reported having received a Pap test within the last 3 years.
Results
Of all women (n=252 391), 72 366 had received a Pap test, and 32 935 of those women (45%, or 12.5 million, weighted) had a prior hysterectomy. We found that age, race/ethnicity, marital status, family income, health status, time since last routine checkup, and health insurance coverage were all significant predictors. Black, non-Hispanic women were 2.23 times more likely to receive Pap testing after a hysterectomy than white women (OR, 2.23; 95% confidence interval [CI], 1.99 to 2.50). Similarly, the odds for Hispanic women were 2.34 times higher (OR, 2.34; 95% CI, 1.97 to 2.80). The odds were also higher for those who were married (OR, 1.17; 95% CI, 1.08 to 1.27), healthier (OR, 1.24; 95% CI, 1.14 to 1.35), and had health insurance (OR, 1.54; 95% CI, 1.28 to 1.84), after controlling for confounders.
Conclusions
We conclude that women may potentially receive Pap tests even if they are not at risk for cervical cancer, and may not be adequately informed about the need for screenings. We recommend strategies to disseminate recommendations and information to patients, their families, and care providers.

Summary

Citations

Citations to this article as recorded by

Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45–65 years of age in the United States
Diane M. Harper, Melissa Plegue, Kathryn M. Harmes, Masahito Jimbo, Sherri SheinfeldGorin
Preventive Medicine.2020; 130: 105880. CrossRef
Socio-demographic Characteristics and Use of Pap Smear for Cervical Cancer Screening Among Women of Eastern Part of India
Dipanwita Ghosh, Sutapa Mahata, Pranab Kumar Sahoo, Sinjini Sarkar, Asoke Roy, Karabi Datta, Manisha Vernekar, Syamsundar Mandal, Vilas D. Nasare
Indian Journal of Gynecologic Oncology.2019;[Epub] CrossRef
2019 Update on Medical Overuse
Daniel J. Morgan, Sanket S. Dhruva, Eric R. Coon, Scott M. Wright, Deborah Korenstein
JAMA Internal Medicine.2019; 179(11): 1568. CrossRef

Author index